Agenus (AGEN) said Wednesday that the first patient has been enrolled in its phase 3 trial evaluating the immunotherapy combination of botensilimab plus balstilimab against standard care in patients with a type of colorectal cancer.

The company said the trial, led by the Canadian Cancer Trials Group, spans Canada, France, Australia and New Zealand, with more than 100 sites participating.